Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803, bNAbs, and haNK cells in HIV-1 infection
NCT04144335Phase 2Withdrawn
- Sponsor
- University of Minnesota
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Cytokines & Interferons, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK in human immunodeficiency virus infection (HIV), sponsored by University of Minnesota. Planned start Jan 2020; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicepthaNK
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04144335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144335.